Meta-analysis topic ideas in diabetes, obesity and endocrinology

Diabetes and obesity are crowded fields. New drug classes arrive quickly, and each one attracts reviews, often before outcome trials are finished. A topic that was open a year ago may now have several competitors.

The most reliable gaps are in populations and outcomes that the headline trials do not cover, and in technology and lifestyle interventions that vary between studies.

Find a endocrinology, diabetes and obesity topic that has not been done

SynthGap searches the published literature, checks each candidate against existing systematic reviews, and proposes topics with the primary studies behind them. The free plan includes 3 discovery runs a month.

Start free

Where gaps tend to hide in diabetes and endocrinology

Newer drugs outside their main indication

Drugs developed for glucose control are now tested for liver disease, kidney outcomes, heart failure and weight. Pooling the trials for a specific secondary outcome may not exist yet.

Type 1 diabetes, adolescents and older adults

Most large trials are in adults with type 2 diabetes. Evidence for other groups is smaller and less often pooled.

Technology

Continuous glucose monitoring, closed-loop systems and digital coaching vary between studies, so narrow, well-defined questions can be open.

Lifestyle and behavioural interventions

Diet, exercise and education programmes differ widely, so reviews restricted to one programme type are often missing.

Thyroid and other endocrine conditions

Smaller specialties such as thyroid, adrenal and pituitary disease have fewer reviews than diabetes.

Outcomes and effect measures that pool well in diabetes and endocrinology

HbA1c change: mean difference. Baseline HbA1c strongly affects how much it falls, so consider baseline level when comparing trials.
Time in range from continuous glucose monitoring: mean difference in percentage points, with the target range stated.
Body weight: mean difference in kilograms or percentage of baseline weight.
Hypoglycaemia: define severe and any hypoglycaemia separately, since trials use different definitions. Risk ratio or rate ratio.
Cardiovascular and kidney outcome trials: hazard ratios for composite and component outcomes.

Common traps in diabetes and endocrinology reviews

HbA1c effects depend on baseline HbA1c, background therapy and whether the drug is added on or used alone.
Short trials (12 to 26 weeks) measure the surrogate, not complications.
Treating a whole drug class as one intervention when individual drugs differ.
Inconsistent definitions of hypoglycaemia and of weight-loss outcomes.

Check before you commit

Before committing months to a topic, check that nobody has beaten you to it. Search PubMed with its systematic review filter, the Cochrane Library, the PROSPERO register (for reviews that are registered but not yet published) and Epistemonikos. Look at how recent the latest review is and whether new trials have appeared since its search date. Step-by-step guide.

Starting points to try in SynthGap

These are areas to explore, not claims that they are open. Some may already be well covered, and finding that out quickly is the point.

Continuous glucose monitoring in adults with type 2 diabetes not using insulin
Weight-loss drugs for people with obesity and chronic kidney disease
Structured education programmes for adolescents with type 1 diabetes

Questions

Which diabetes topics are probably crowded?

Comparisons of the main drug classes for HbA1c in adults with type 2 diabetes have many reviews and network meta-analyses. Narrow by population, outcome or intervention type.

How do I pool HbA1c across trials with different baselines?

Use the mean change from baseline with its standard error, and explore baseline HbA1c in a meta-regression or subgroup analysis if enough studies are available.

Is a network meta-analysis worth doing for a new drug class?

Only if there are enough comparable trials of the new drug against several comparators. Otherwise a pairwise review of the best-studied comparison is more reliable.

Other specialties

This page is general methodological guidance, not medical advice, and it does not list specific unreviewed topics. SynthGap's suggestions are AI-generated from the published literature, so verify them before registering a protocol.